Donor cell boost aims to rescue failed stem cell transplants

NCT ID NCT06569082

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a procedure called a CD34+ selected donor cell boost for people whose stem cell transplant has not worked well (graft failure or poor function). The donor's blood stem cells are separated using a special system and then infused back into the patient to help restore normal blood cell production. The trial will enroll 21 adults and measure whether blood cell counts improve without needing transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD34+ selected donor cells (CliniMACS CD34 Reagent System)
What this could lead to: If successful, this could offer a way to restore blood cell production in patients whose stem cell transplant has failed, reducing the need for additional transfusions.
What could go wrong: This is a very small, early pilot study with only 21 participants, so results may not apply to everyone. There are risks of graft-versus-host disease (GVHD) and the procedure may not work for all types of graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT FAILURE POOR GRAFT FUNCTION

Contacts and locations

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.